Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys

Fu, Tong-Ming; Grimm, Karen M.; Citron, Michael; Freed, Daniel C.; Fan, Jun; Keller, Paul M.; Shiver, John W.; Liang, Xiaoping; Joyce, Joseph G.

doi:10.1016/j.vaccine.2008.12.034

Cited by 75 publications

(60 citation statements)

References 50 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Examples include CCR5 peptide-VLP conjugates for HIV [259], M2 peptide-VLP conjugate for influenza [260], nicotine-VLP conjugates via succinimate linkers for nicotine addiction [261]. It should be noted that VLPs may not be very stable in an aqueous solution and could be responsible for lower-than-expected immunogenicity [262]. Conjugation of VLPs with haptens may improve the stability of VPLs [260].…”

Section: Virus-like Particles (Vlps)mentioning

confidence: 99%

Selection of Adjuvants for Enhanced Vaccine Potency

Wang¹,

Singh²

2011

WJV

View full text Add to dashboard Cite

show abstract

Section: Virus-like Particles (Vlps)mentioning

confidence: 99%

Selection of Adjuvants for Enhanced Vaccine Potency

Wang¹,

Singh²

2011

WJV

View full text Add to dashboard Cite

show abstract

“…Although the recently emerged pandemic influenza A California strain exhibits four mutations within this domain, the C-terminal 11 amino acid have been completely conserved. In addition, M2e-specific antibodies protect mice [15][16][17][18][19][20], ferrets, and monkeys [21,22] from infection with various different flu strains. Hence, M2e-based vaccines may be promising candidates for pandemics since they could be stockpiled in large amounts prior to the event.…”

Section: Introductionmentioning

confidence: 99%

“…2012. 42: 863-869 and monkeys [21,22] from infection with various different flu strains. Hence, M2e-based vaccines may be promising candidates for pandemics since they could be stockpiled in large amounts prior to the event.…”

mentioning

confidence: 99%

Universal vaccine against influenza virus: Linking TLR signaling to anti‐viral protection

Schmitz¹,

Beerli²,

Bauer³

et al. 2012

Eur J Immunol

View full text Add to dashboard Cite

A vaccine protecting against all influenza strains is a long-sought goal, particularly for emerging pandemics. As previously shown, vaccines based on the highly conserved extracellular domain of M2 (M2e) may protect against all influenza A strains. Here, we demonstrate that M2e-specific monoclonal antibodies (mAbs) protect mice from a lethal influenza infection. To be protective, antibodies had to be able to bind to Fc receptors and fix complement. Furthermore, mAbs of IgG2c isotype were protective in mice, while antibodies of identical specificity, but of the IgG1 isotype, failed to prevent disease. These findings readily translated into vaccine design. A vaccine targeting M2 in the absence of a toll-like receptor (TLR) 7 ligand primarily induced IgG1, whilst the same vaccine linked to a TLR7 ligand yielded high levels of IgG2c antibodies. Although both vaccines protected mice from a lethal challenge, mice treated with the vaccine containing a TLR7 ligand showed significantly lower morbidity. In accordance with these findings, vaccination of TLR7 -/-mice with a vaccine containing a TLR7 ligand did not result in protection from a lethal challenge. Hence, the innate immune system is required to direct isotype switching toward the more protective IgG2a/c antibodies.Keywords: Antibodies r Immunotherapy r Toll like receptors r Vaccination r Virology IntroductionInfection with influenza virus is a major cause of morbidity as well as mortality throughout the world. Influenza virus is a very dynamic pseudo species and constantly avoids immunity at the population level by accumulating mutations in the hemagglutinin (HA) and neuraminidase molecules in a process called genetic drift. In addition, in a rare process called genetic shift, human influenza viruses may reassort with avian or swine influenza viruses [1]. Since under these circumstances, the virus hits an essentially naive population, the epidemic may become a pandemic with potentially millions of people infected and killed by the virus.Correspondence: Dr. Martin F. Bachmann e-mail: martin.bachmann@me.com Induction of protective immunity against influenza virus, not affected by genetic drift or shift, is therefore a major goal in vaccine development [2,3]. T cells are usually more cross-reactive than antibodies [4][5][6] and additionally recognize more conserved, virus-internal proteins [7,8]. Induction of broadly reactive T cells by vaccination may therefore be a potential avenue to follow [9,10]. This, however, may be a difficult task, since protective T-cell responses are usually short lived in mice [11] and humans [12], and it has not been possible so far to induce long-lived T-cell mediated immunity by vaccination. An alternative approach represents the induction of protective antibody responses directed against conserved viral structures. The extracellular domain of M2 (M2e) is a candidate for such a vaccine. M2e is highly conserved in all influenza A strains and has hardly changed over the last 90 years [13,14]. Although the recently emerged pandemic influ...

show abstract

“…However, despite the presence of the invariant domain of M2, humans lack antibody responses to M2 after vaccination or natural infection, indicating that M2 is poorly immunogenic (3). Previous studies reported immunization with M2e peptide fusion constructs linked to carrier vehicles as vaccine candidates (4)(5)(6). Antibodies to M2e have been shown to provide protection against lethal infection in animal models.…”

mentioning

confidence: 99%

Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus

Song

Rooijen

Bozja³

et al. 2010

Proc. Natl. Acad. Sci. U.S.A.

137

120

View full text Add to dashboard Cite

Development of an influenza vaccine that provides broadly cross-protective immunity has been a scientific challenge for more than half a century. This study presents an approach to overcome strain-specific protection by supplementing conventional vaccines with virus-like particles (VLPs) containing the conserved M2 protein (M2 VLPs) in the absence of adjuvants. We demonstrate that an inactivated influenza vaccine supplemented with M2 VLPs prevents disease symptoms without showing weight loss and confers complete cross protection against lethal challenge with heterologous influenza A viruses including the 2009 H1N1 pandemic virus as well as heterosubtypic H3N2 and H5N1 influenza viruses. Cross-protective immunity was long-lived, for more than 7 mo. Immune sera from mice immunized with M2 VLP supplemented vaccine transferred cross protection to naive mice. Dendritic and macrophage cells were found to be important for this cross protection mediated by immune sera. The results provide evidence that supplementation of seasonal influenza vaccines with M2 VLPs is a promising approach for overcoming the limitation of strain-specific protection by current vaccines and developing a universal influenza A vaccine.

show abstract

Comparative immunogenicity evaluations of influenza A virus M2 peptide as recombinant virus like particle or conjugate vaccines in mice and monkeys

Cited by 75 publications

References 50 publications

Selection of Adjuvants for Enhanced Vaccine Potency

Selection of Adjuvants for Enhanced Vaccine Potency

Universal vaccine against influenza virus: Linking TLR signaling to anti‐viral protection

Vaccination inducing broad and improved cross protection against multiple subtypes of influenza A virus

Contact Info

Product

Resources

About